Overview

Assessing PA-824 for Tuberculosis (the APT Trial)

Status:
Recruiting

Trial end date:
2022-09-01

Target enrollment:

Participant gender:

Summary

Assess the mycobactericidal activity of PA-824 (given at 200 mg daily) when added to first-line tuberculosis (TB) treatment (isoniazid, pyrazinamide, and a rifamycin antibiotic) over 12 weeks of treatment. Funding Source - FDA OOPD

Phase:

Phase 2

Details

Lead Sponsor:

Johns Hopkins University

Collaborator:

University of Cape Town

Treatments:

Ethambutol
Isoniazid
Pyrazinamide
Rifabutin
Rifampin